期刊文献+

HPLC法测定阿哌沙班中的有关物质 被引量:7

下载PDF
导出
摘要 目的:采用HPLC法测定阿哌沙班中的有关物质。方法:色谱柱为Agilent SB-C18(250 mm×4.6 mm,5μm);流动相为甲醇-0.01 mol/L磷酸二氢铵(用稀磷酸调到p H 3.0)(65∶35);检测波长为266 nm;柱温为35℃;流速为1.0 ml/min。结果:阿哌沙班浓度在0.25~2.0μg/ml范围内,峰面积与浓度线性关系好(r=0.999 6),最低检出限为0.05μg/ml(S/N=3),定量限为0.2μg/ml(S/N=10)。结论:所用方法专属性强、准确、简便、快速,适用于阿哌沙班中有关物质的检查。
作者 张震 孙燕
出处 《天津药学》 2014年第6期9-11,共3页 Tianjin Pharmacy
  • 相关文献

参考文献3

二级参考文献43

  • 1Donald JP, Michael JO, Stephanie K, et al. Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin- 1-yl) phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3- carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa[J]. J Med Chem, 2007, 50(22): 5339-5356.
  • 2Kylie L, Mark C. New anticoagulants for the prevention of thromboembolism[J]. Curr Phar Des, 2010, 16(31): 3472- 3474.
  • 3Ann KW. New oral anticoagulants: a practical guide for clinicians[J]. J Thromb Thrombolysis, 2010, 29(2): 182-191.
  • 4Donglu Z, Kan H, Nirmala R, et al. Metabolism,pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits[J]. J Thromb Thrombolysis, 2010, 29(1): 70-80.
  • 5Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos, 2008, 37(1 ): 74-81.
  • 6John WE, Martin OD, Salim Y, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment[J]. Am Heart J, 2010, 159(3): 348-353.
  • 7Jennifer C, Jack A. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict[J]. Expert Opin Investig Dru2s. 2008. 17(12: 1937-1945.
  • 8Roser-Jones C, Becker RC. Apixaban: an emerging oral factor Xa inhibitor[J]. J Thromb Thrombolysis, 2010, 29(1): 141- 146.
  • 9Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement[J]. J Thromb Haemost, 2007, 5(12): 2368-2375.
  • 10Michael RL, Gary ER, Alexander G, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial[J]. Lancet, 2010, 375(9717): 807-815.

共引文献372

同被引文献49

引证文献7

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部